tamoxifen 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2561	10540-29-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tamoxifen tamoxifen citrate tamoxifene tamoxifene citrate	One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. Molecular weight: 371.52 Formula: C26H29NO CLOGP: 6.82 LIPINSKI: 1 HAC: 2 HDO: 0 TPSA: 12.47 ALOGS: -5.56 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tamoxifen
tamoxifen citrate
tamoxifene
tamoxifene citrate

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Molecular weight: 371.52
Formula: C26H29NO
CLOGP: 6.82
LIPINSKI: 1
HAC: 2
HDO: 0
TPSA: 12.47
ALOGS: -5.56
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.50 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.18 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Dec. 30, 1977	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Metastases to bone	1434.74	11.37	517	33872	17478	50553257
Malignant neoplasm progression	1369.95	11.37	742	33647	67382	50503353
Metastases to liver	793.98	11.37	348	34041	19756	50550979
Metastases to lung	474.91	11.37	203	34186	10817	50559918
Metastases to lymph nodes	428.28	11.37	166	34223	6858	50563877
Breast cancer recurrent	389.86	11.37	132	34257	3676	50567059
Disease progression	369.21	11.37	387	34002	95479	50475256
Breast cancer metastatic	362.80	11.37	165	34224	10199	50560536
Neoplasm progression	342.12	11.37	225	34164	28932	50541803
Osteonecrosis of jaw	232.68	11.37	186	34203	32340	50538395
Breast cancer	205.18	11.37	195	34194	42695	50528040
Metastasis	183.17	11.37	79	34310	4296	50566439
Uterine polyp	160.39	11.37	56	34333	1712	50569023
Metastases to central nervous system	159.50	11.37	98	34291	11184	50559551
Metastases to spine	144.94	11.37	59	34330	2772	50567963
Hot flush	143.08	11.37	163	34226	44006	50526729
Endometrial hyperplasia	139.86	11.37	41	34348	701	50570034
Osteonecrosis	136.46	11.37	117	34272	22400	50548335
Bone disorder	133.55	11.37	107	34282	18645	50552090
Second primary malignancy	129.28	11.37	72	34317	6842	50563893
PIK3CA-activated mutation	119.26	11.37	37	34352	773	50569962
Bone lesion	113.83	11.37	60	34329	5110	50565625
Hormone receptor positive breast cancer	110.14	11.37	31	34358	455	50570280
Acute myeloid leukaemia	109.44	11.37	87	34302	14987	50555748
Drug ineffective	106.38	11.37	252	34137	819081	49751654
Sarcoma uterus	101.35	11.37	18	34371	17	50570718
Tumour marker increased	100.29	11.37	50	34339	3790	50566945
Endometrial hypertrophy	97.33	11.37	25	34364	253	50570482
Metastases to pleura	94.52	11.37	35	34354	1271	50569464
Neuropathy peripheral	94.15	11.37	205	34184	96552	50474183
Hepatic lesion	86.78	11.37	46	34343	3962	50566773
Contraindicated product administered	81.32	11.37	5	34384	148953	50421782
Hysteroscopy	80.50	11.37	15	34374	23	50570712
Metastases to the mediastinum	79.99	11.37	24	34365	446	50570289
Palmar-plantar erythrodysaesthesia syndrome	78.70	11.37	82	34307	20016	50550719
Osteolysis	77.92	11.37	37	34352	2520	50568215
Rheumatoid arthritis	77.36	11.37	21	34368	202529	50368206
Pseudocirrhosis	77.12	11.37	25	34364	605	50570130
Endometrial cancer	76.65	11.37	38	34351	2845	50567890
Systemic lupus erythematosus	75.93	11.37	5	34384	140617	50430118
Metastases to peritoneum	74.31	11.37	37	34352	2796	50567939
Device related thrombosis	72.99	11.37	29	34360	1278	50569457
Joint swelling	71.27	11.37	39	34350	245247	50325488
Bone pain	70.46	11.37	120	34269	47109	50523626
Death	69.87	11.37	418	33971	324961	50245774
Tonsillar disorder	68.60	11.37	26	34363	1008	50569727
Metastases to skin	67.99	11.37	28	34361	1355	50569380
Recurrent cancer	67.92	11.37	30	34359	1727	50569008
Neutropenia	66.17	11.37	236	34153	147729	50423006
Glossodynia	65.82	11.37	3	34386	115566	50455169
Endometrial atrophy	65.64	11.37	14	34375	56	50570679
Therapeutic product effect decreased	64.98	11.37	8	34381	136042	50434693
Blood uric acid decreased	63.39	11.37	22	34367	660	50570075
Nail disorder	59.93	11.37	51	34338	9657	50561078
Synovitis	59.85	11.37	7	34382	123858	50446877
Carbohydrate antigen 15-3 increased	59.35	11.37	24	34365	1108	50569627
Pleural effusion	59.07	11.37	154	34235	81300	50489435
Uterine cancer	58.66	11.37	35	34354	3785	50566950
Lymphoedema	58.53	11.37	49	34340	9073	50561662
Lymphadenopathy	57.93	11.37	91	34298	33408	50537327
Acute promyelocytic leukaemia	57.82	11.37	22	34367	862	50569873
Nasal disorder	57.18	11.37	29	34360	2279	50568456
Endocervical curettage	56.65	11.37	9	34380	0	50570735
Eosinophil percentage increased	56.10	11.37	22	34367	936	50569799
Ovarian hyperstimulation syndrome	55.83	11.37	32	34357	3212	50567523
Metastases to pelvis	55.12	11.37	17	34372	348	50570387
Ascites	53.33	11.37	91	34298	35770	50534965
Excessive eye blinking	52.86	11.37	21	34368	925	50569810
Abdominal discomfort	51.40	11.37	49	34340	231592	50339143
Breast mass	50.65	11.37	39	34350	6410	50564325
Pulmonary mass	50.59	11.37	63	34326	18642	50552093
Metastases to thorax	49.46	11.37	14	34375	210	50570525
Maternal exposure during pregnancy	48.46	11.37	24	34365	159754	50410981
Recall phenomenon	48.09	11.37	17	34372	539	50570196
Tooth extraction	46.69	11.37	43	34346	9032	50561703
Endometriosis	46.66	11.37	31	34358	4044	50566691
Breast cancer female	46.40	11.37	38	34351	6824	50563911
Wound	46.39	11.37	8	34381	105786	50464949
Completed suicide	46.14	11.37	16	34373	131873	50438862
Hepatic enzyme increased	45.81	11.37	18	34371	137362	50433373
Disease recurrence	45.53	11.37	62	34327	20019	50550716
Lymphangiosis carcinomatosa	44.88	11.37	20	34369	1176	50569559
Ovarian cancer	44.56	11.37	33	34356	5116	50565619
Left ventricular dilatation	44.44	11.37	15	34374	413	50570322
Peritoneal disorder	43.77	11.37	15	34374	433	50570302
Dural arteriovenous fistula	43.45	11.37	8	34381	11	50570724
Metastases to ovary	43.29	11.37	14	34375	336	50570399
Vitreous detachment	42.87	11.37	22	34367	1772	50568963
Metastases to chest wall	42.82	11.37	15	34374	463	50570272
Retinopathy	42.04	11.37	25	34364	2687	50568048
Hypertriglyceridaemia	40.51	11.37	32	34357	5459	50565276
Ejection fraction decreased	40.21	11.37	56	34333	18464	50552271
Haematotoxicity	39.83	11.37	37	34352	7858	50562877
Polyneuropathy	39.64	11.37	45	34344	12086	50558649
Metastatic neoplasm	39.26	11.37	27	34362	3727	50567008
Cerebral venous thrombosis	39.17	11.37	21	34368	1850	50568885
Sinusitis	39.09	11.37	35	34354	170523	50400212
Lymphadenopathy mediastinal	38.54	11.37	23	34366	2488	50568247
Onycholysis	36.78	11.37	18	34371	1310	50569425
Pneumonia	36.69	11.37	133	34256	378268	50192467
Metastases to muscle	36.44	11.37	10	34379	133	50570602
Bronchomalacia	36.34	11.37	11	34378	211	50570524
Vulvovaginal dryness	35.84	11.37	21	34368	2196	50568539
Hypersensitivity	35.64	11.37	57	34332	215104	50355631
Exposure during pregnancy	35.46	11.37	19	34370	120996	50449739
Pulmonary embolism	35.44	11.37	150	34239	101554	50469181
Swelling	35.40	11.37	51	34338	200821	50369914
BRAF gene mutation	34.97	11.37	8	34381	47	50570688
Spinal cord compression	34.89	11.37	25	34364	3684	50567051
Rash	34.81	11.37	166	34223	437305	50133430
Endometrial disorder	34.75	11.37	14	34375	640	50570095
Portal hypertension	34.54	11.37	24	34365	3368	50567367
Endometrial thickening	34.21	11.37	11	34378	259	50570476
Exposed bone in jaw	33.76	11.37	22	34367	2778	50567957
Drug hypersensitivity	33.26	11.37	76	34313	250934	50319801
Condition aggravated	33.21	11.37	98	34291	296960	50273775
Blood creatinine decreased	32.48	11.37	27	34362	4949	50565786
Hepatic cirrhosis	32.13	11.37	49	34340	17528	50553207
Bone cancer metastatic	32.04	11.37	9	34380	131	50570604
Metastases to uterus	31.89	11.37	8	34381	73	50570662
Treatment failure	31.82	11.37	28	34361	137609	50433126
Hypertransaminasaemia	30.93	11.37	23	34366	3588	50567147
Infusion related reaction	30.92	11.37	42	34347	169515	50401220
Uterine leiomyoma	30.54	11.37	32	34357	7859	50562876
Pleural disorder	30.05	11.37	12	34377	536	50570199
Hydrothorax	29.94	11.37	13	34376	718	50570017
Menopause	29.82	11.37	19	34370	2308	50568427
Malignant pleural effusion	29.80	11.37	19	34370	2311	50568424
Menopausal disorder	29.54	11.37	7	34382	49	50570686
Tumour invasion	29.53	11.37	8	34381	101	50570634
Osteosclerosis	29.51	11.37	22	34367	3445	50567290
Product use issue	29.35	11.37	35	34354	149440	50421295
Cervical polyp	28.74	11.37	9	34380	194	50570541
Adenocarcinoma	28.71	11.37	19	34370	2462	50568273
Invasive ductal breast carcinoma	28.43	11.37	27	34362	5894	50564841
Nasopharyngitis	28.41	11.37	55	34334	192872	50377863
Acquired gene mutation	28.34	11.37	13	34376	818	50569917
Adnexa uteri mass	27.98	11.37	11	34378	471	50570264
Radiation skin injury	27.87	11.37	13	34376	850	50569885
Radiation necrosis	27.82	11.37	10	34379	333	50570402
Left ventricular dysfunction	27.79	11.37	35	34354	10471	50560264
Uterine dilation and curettage	27.74	11.37	13	34376	859	50569876
Cardiac cirrhosis	27.61	11.37	8	34381	131	50570604
Neoplasm recurrence	27.07	11.37	18	34371	2351	50568384
Osteitis condensans	26.88	11.37	6	34383	31	50570704
Pericarditis	26.74	11.37	10	34379	78679	50492056
Injection site pain	26.38	11.37	22	34367	111002	50459733
Oestradiol abnormal	26.26	11.37	6	34383	35	50570700
Mucosal inflammation	26.17	11.37	73	34316	40069	50530666
RET gene mutation	25.99	11.37	5	34384	10	50570725
Jaw operation	25.97	11.37	12	34377	768	50569967
Gastrointestinal toxicity	25.71	11.37	23	34366	4654	50566081
Breast cancer stage IV	25.43	11.37	11	34378	602	50570133
Porphyria non-acute	25.38	11.37	9	34380	288	50570447
Tympanic membrane disorder	25.27	11.37	8	34381	179	50570556
Radiation pneumonitis	25.22	11.37	14	34375	1321	50569414
Drug abuse	25.21	11.37	5	34384	59841	50510894
Metastases to stomach	25.02	11.37	8	34381	185	50570550
Bone sequestrum	24.81	11.37	14	34375	1364	50569371
Malignant neoplasm of pleura	24.73	11.37	6	34383	47	50570688
Mucosal toxicity	24.67	11.37	9	34380	313	50570422
Pain in jaw	24.18	11.37	69	34320	38359	50532376
Gingival bleeding	24.15	11.37	34	34355	11319	50559416
Arthropathy	24.14	11.37	44	34345	157862	50412873
Tumour marker decreased	23.61	11.37	6	34383	58	50570677
Actinomycosis	23.49	11.37	12	34377	957	50569778
Pain	23.15	11.37	267	34122	578636	49992099
Deprescribing error	23.06	11.37	5	34384	22	50570713
Jaw disorder	22.71	11.37	22	34367	4921	50565814
Vaginal haemorrhage	22.69	11.37	51	34338	24500	50546235
Leiomyoma	22.60	11.37	9	34380	399	50570336
Pathological fracture	22.60	11.37	27	34362	7655	50563080
Central nervous system lesion	22.58	11.37	30	34359	9459	50561276
Maculopathy	22.56	11.37	15	34374	1959	50568776
Sequestrectomy	22.42	11.37	11	34378	805	50569930
Dental operation	22.13	11.37	12	34377	1081	50569654
Metastases to breast	22.02	11.37	8	34381	275	50570460
Hysterectomy	22.02	11.37	27	34362	7863	50562872
Metastases to bone marrow	21.99	11.37	8	34381	276	50570459
Skin hypopigmentation	21.92	11.37	10	34379	621	50570114
Eastern Cooperative Oncology Group performance status worsened	21.82	11.37	10	34379	628	50570107
Hepatic steatosis	21.81	11.37	50	34339	24334	50546401
Fibrous histiocytoma	21.57	11.37	9	34380	450	50570285
Malignant neoplasm of choroid	21.52	11.37	4	34385	6	50570729
Toothache	21.42	11.37	40	34349	16854	50553881
HER2 positive breast cancer	21.28	11.37	8	34381	303	50570432
Invasive lobular breast carcinoma	21.28	11.37	10	34379	665	50570070
Abdominal lymphadenopathy	21.20	11.37	10	34379	671	50570064
Atrophic vulvovaginitis	20.38	11.37	13	34376	1583	50569152
Jaundice	20.20	11.37	51	34338	26378	50544357
Osteomyelitis	20.17	11.37	46	34343	22307	50548428
Infection	20.07	11.37	56	34333	172898	50397837
Injection site extravasation	19.86	11.37	25	34364	7476	50563259
Discomfort	19.59	11.37	27	34362	108353	50462382
Neoplasm	19.38	11.37	22	34367	5906	50564829
Meningeal disorder	19.26	11.37	7	34382	241	50570494
Therapy partial responder	19.11	11.37	23	34366	6568	50564167
Polypectomy	19.00	11.37	9	34380	609	50570126
Congestive cardiomyopathy	18.93	11.37	21	34368	5497	50565238
Amenorrhoea	18.93	11.37	26	34363	8458	50562277
Pulmonary radiation injury	18.88	11.37	3	34386	0	50570735
Uterine polypectomy	18.88	11.37	3	34386	0	50570735
Weight increased	18.84	11.37	72	34317	201819	50368916
Ovarian cyst	18.83	11.37	34	34355	13962	50556773
Carcinoembryonic antigen increased	18.80	11.37	12	34377	1462	50569273
Portal vein thrombosis	18.75	11.37	14	34375	2198	50568537
Oestrogen receptor assay positive	18.54	11.37	8	34381	435	50570300
Neutrophilia	18.51	11.37	17	34372	3558	50567177
Adenomyosis	18.19	11.37	8	34381	456	50570279
Product dose omission issue	18.18	11.37	64	34325	183774	50386961
Myelodysplastic syndrome	18.16	11.37	35	34354	15097	50555638
Gastrointestinal haemorrhage	18.07	11.37	14	34375	73307	50497428
Breath odour	18.04	11.37	11	34378	1237	50569498
Activated PI3 kinase delta syndrome	18.03	11.37	4	34385	20	50570715
Oophorectomy	17.97	11.37	8	34381	469	50570266
Lymphangioleiomyomatosis	17.96	11.37	6	34383	160	50570575
Cardiotoxicity	17.94	11.37	23	34366	7004	50563731
Toxicity to various agents	17.82	11.37	79	34310	212420	50358315
Disturbance in attention	17.72	11.37	54	34335	31132	50539603
Peripheral swelling	17.61	11.37	76	34313	205860	50364875
Breast disorder	17.59	11.37	13	34376	2009	50568726
Aeromonas infection	17.54	11.37	5	34384	77	50570658
Breast neoplasm	17.53	11.37	11	34378	1302	50569433
Corneal degeneration	17.48	11.37	5	34384	78	50570657
Menopausal symptoms	17.47	11.37	13	34376	2030	50568705
Macular hole	17.43	11.37	9	34380	734	50570001
Somnolence	17.38	11.37	51	34338	154934	50415801
Therapeutic product effect incomplete	17.35	11.37	22	34367	91493	50479242
Corneal graft rejection	17.14	11.37	4	34385	26	50570709
Paraneoplastic syndrome	17.12	11.37	8	34381	525	50570210
Headache	17.11	11.37	242	34147	506293	50064442
Respiratory tract inflammation	17.02	11.37	8	34381	532	50570203
Ventricular hypokinesia	16.96	11.37	17	34372	3963	50566772
Pruritus	16.91	11.37	118	34271	283450	50287285
Oxygen saturation decreased	16.80	11.37	15	34374	73233	50497502
Cortisol increased	16.72	11.37	7	34382	353	50570382
Intentional overdose	16.63	11.37	11	34378	62493	50508242
Diabetic hyperosmolar coma	16.56	11.37	7	34382	362	50570373
Loss of personal independence in daily activities	16.49	11.37	14	34375	70036	50500699
Contusion	16.49	11.37	32	34357	112151	50458584
Invasive breast carcinoma	16.41	11.37	8	34381	577	50570158
Acute lymphocytic leukaemia	16.40	11.37	13	34376	2228	50568507
Atrial thrombosis	16.34	11.37	11	34378	1466	50569269
Sensory loss	16.20	11.37	23	34366	7715	50563020
Performance status decreased	16.17	11.37	15	34374	3180	50567555
Debridement	16.05	11.37	10	34379	1169	50569566
Gingivitis	15.77	11.37	22	34367	7262	50563473
Myalgia	15.75	11.37	141	34248	124178	50446557
Libido decreased	15.73	11.37	13	34376	2363	50568372
Acarodermatitis	15.56	11.37	9	34380	919	50569816
Hypotension	15.54	11.37	95	34294	235374	50335361
Arteriovenous malformation	15.45	11.37	10	34379	1248	50569487
Liver scan abnormal	15.44	11.37	4	34385	42	50570693
Oral pustule	15.44	11.37	4	34385	42	50570693
Salpingitis	15.42	11.37	6	34383	250	50570485
Intermenstrual bleeding	15.38	11.37	21	34368	6793	50563942
Uterine haemorrhage	15.32	11.37	15	34374	3400	50567335
Septic shock	15.29	11.37	10	34379	57165	50513570
Rapidly progressive osteoarthritis	15.28	11.37	3	34386	7	50570728
Respiratory tract oedema	15.25	11.37	7	34382	441	50570294
Metastases to eye	15.19	11.37	5	34384	127	50570608
Blood alkaline phosphatase increased	15.18	11.37	58	34331	37468	50533267
Central nervous system infection	15.13	11.37	8	34381	685	50570050
Acute kidney injury	15.06	11.37	92	34297	227966	50342769
Blood bilirubin increased	15.06	11.37	52	34337	31986	50538749
Paraesthesia	15.04	11.37	136	34253	120107	50450628
Urticaria	14.99	11.37	42	34347	129519	50441216
Rhabdomyolysis	14.96	11.37	4	34385	39023	50531712
Deafness	14.95	11.37	33	34356	15658	50555077
Vertebral lesion	14.92	11.37	7	34382	464	50570271
Haemangioma of liver	14.87	11.37	9	34380	999	50569736
Chronic hepatic failure	14.78	11.37	7	34382	474	50570261
Periodontitis	14.74	11.37	14	34375	3055	50567680
Blood follicle stimulating hormone decreased	14.73	11.37	3	34386	9	50570726
Oesophageal varices haemorrhage	14.69	11.37	9	34380	1021	50569714
Alopecia	14.59	11.37	102	34287	244945	50325790
Cerebral haemorrhage	14.59	11.37	46	34343	27006	50543729
Salpingo-oophorectomy bilateral	14.57	11.37	5	34384	145	50570590
Coagulation factor V level decreased	14.50	11.37	6	34383	294	50570441
Blood copper increased	14.49	11.37	3	34386	10	50570725
Musculoskeletal chest pain	14.47	11.37	36	34353	18450	50552285
Skin exfoliation	14.47	11.37	53	34336	33559	50537176
Blood follicle stimulating hormone increased	14.38	11.37	5	34384	151	50570584
Primary adrenal insufficiency	14.32	11.37	4	34385	57	50570678
Breast cancer in situ	14.28	11.37	10	34379	1421	50569314
Adenoid cystic carcinoma	14.27	11.37	3	34386	11	50570724
Non-alcoholic steatohepatitis	14.25	11.37	10	34379	1425	50569310
Injection site erythema	14.22	11.37	18	34371	74918	50495817
Blood lactate dehydrogenase increased	14.18	11.37	37	34352	19525	50551210
Trigger finger	14.01	11.37	15	34374	3773	50566962
Atypical femur fracture	14.00	11.37	17	34372	4899	50565836
Cardiomyopathy	13.98	11.37	32	34357	15554	50555181
Ocular toxicity	13.95	11.37	7	34382	538	50570197
Retinal artery occlusion	13.93	11.37	10	34379	1477	50569258
Varices oesophageal	13.93	11.37	13	34376	2776	50567959
Pelvic mass	13.86	11.37	9	34380	1130	50569605
Encephalopathy	13.82	11.37	3	34386	33708	50537027
Blister	13.77	11.37	23	34366	85395	50485340
Multiple sclerosis relapse	13.71	11.37	6	34383	42958	50527777
Hepatic cancer metastatic	13.66	11.37	6	34383	341	50570394
Nasal congestion	13.59	11.37	9	34380	51111	50519624
Oral mucosal hypertrophy	13.52	11.37	3	34386	15	50570720
Diverticulitis	13.50	11.37	3	34386	33179	50537556
Visual acuity reduced	13.49	11.37	37	34352	20102	50550633
Postmenopausal haemorrhage	13.46	11.37	11	34378	1969	50568766
Metastases to neck	13.45	11.37	4	34385	72	50570663
Sepsis	13.32	11.37	46	34343	132879	50437856
Papillary thyroid cancer	13.29	11.37	11	34378	2004	50568731
Knee arthroplasty	13.14	11.37	4	34385	35842	50534893
Corneal disorder	13.13	11.37	10	34379	1616	50569119
Nasal dryness	12.94	11.37	14	34375	3565	50567170
Madarosis	12.92	11.37	12	34377	2548	50568187
Drug resistance	12.83	11.37	35	34354	18954	50551781
Reversible cerebral vasoconstriction syndrome	12.81	11.37	11	34378	2108	50568627
Oestradiol increased	12.78	11.37	4	34385	86	50570649
Internal fixation of fracture	12.66	11.37	7	34382	655	50570080
Hepatotoxicity	12.63	11.37	44	34345	27182	50543553
Eosinophil count increased	12.59	11.37	22	34367	8808	50561927
Myocardial infarction	12.56	11.37	26	34363	89001	50481734
Lower limb fracture	12.50	11.37	29	34360	14217	50556518
Neoplasm malignant	12.49	11.37	40	34349	23675	50547060
Breast reconstruction	12.48	11.37	5	34384	225	50570510
Desmoid tumour	12.41	11.37	4	34385	95	50570640
Vein disorder	12.41	11.37	15	34374	4304	50566431
Purulent discharge	12.37	11.37	15	34374	4317	50566418
Alopecia areata	12.36	11.37	9	34380	1359	50569376
Breast pain	12.36	11.37	20	34369	7524	50563211
Metastases to adrenals	12.36	11.37	7	34382	687	50570048
Retroperitoneal neoplasm metastatic	12.31	11.37	3	34386	24	50570711
Abdominal pain upper	12.30	11.37	61	34328	159248	50411487
Incorrect dose administered	12.24	11.37	9	34380	48405	50522330
Superior sagittal sinus thrombosis	12.23	11.37	7	34382	700	50570035
Pneumonia aspiration	12.23	11.37	3	34386	31001	50539734
Dental caries	12.06	11.37	23	34366	9844	50560891
Tooth disorder	11.98	11.37	40	34349	24188	50546547
Influenza	11.93	11.37	27	34362	89511	50481224
Endometrial adenocarcinoma	11.88	11.37	8	34381	1067	50569668
Bile duct stenosis	11.87	11.37	8	34381	1068	50569667
Hydronephrosis	11.81	11.37	21	34368	8520	50562215
Injection site reaction	11.77	11.37	10	34379	50022	50520713
Folliculitis	11.71	11.37	6	34383	39219	50531516
Intestinal metastasis	11.69	11.37	4	34385	115	50570620
Fungal disease carrier	11.62	11.37	3	34386	31	50570704
Ovarian granulosa-theca cell tumour	11.62	11.37	3	34386	31	50570704
HER2 gene amplification	11.62	11.37	3	34386	31	50570704
Psoriatic arthropathy	11.56	11.37	9	34380	47023	50523712
Glutamate dehydrogenase increased	11.45	11.37	3	34386	33	50570702
Heart rate irregular	11.44	11.37	34	34355	19326	50551409

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Metastases to bone	81.86	28.34	25	1042	9873	29563587
Carbohydrate antigen 15-3 increased	63.67	28.34	9	1058	69	29573391
Metastases to lung	44.92	28.34	15	1052	7840	29565620
Metastases to central nervous system	34.43	28.34	12	1055	7119	29566341
Malignant neoplasm progression	33.87	28.34	25	1042	73834	29499626
Metastases to the mediastinum	33.55	28.34	6	1061	223	29573237
PIK3CA-activated mutation	31.19	28.34	5	1062	95	29573365
Hepatic lesion	30.50	28.34	9	1058	3141	29570319

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Metastases to bone	1150.36	12.26	401	26799	20034	64451498
Malignant neoplasm progression	751.07	12.26	510	26690	112361	64359171
Metastases to liver	496.82	12.26	229	26971	23712	64447820
Metastases to lung	429.89	12.26	181	27019	15083	64456449
Metastases to lymph nodes	348.26	12.26	133	27067	8584	64462948
Breast cancer metastatic	310.34	12.26	116	27084	7053	64464479
Breast cancer recurrent	308.52	12.26	90	27110	2493	64469039
Breast cancer	220.51	12.26	143	27057	29005	64442527
Neoplasm progression	211.57	12.26	159	27041	40805	64430727
Osteonecrosis of jaw	189.00	12.26	147	27053	39678	64431854
Disease progression	184.31	12.26	261	26939	141419	64330113
Metastases to central nervous system	140.24	12.26	82	27118	13830	64457702
Metastases to spine	136.25	12.26	53	27147	3590	64467942
Hot flush	121.40	12.26	122	27078	46113	64425419
Bone lesion	118.67	12.26	53	27147	5084	64466448
Sarcoma uterus	116.72	12.26	18	27182	6	64471526
Tumour marker increased	107.50	12.26	44	27156	3406	64468126
Osteonecrosis	102.06	12.26	89	27111	28140	64443392
Second primary malignancy	96.90	12.26	62	27138	12275	64459257
Acute myeloid leukaemia	94.12	12.26	84	27116	27379	64444153
Metastases to skin	91.29	12.26	31	27169	1421	64470111
Metastasis	89.31	12.26	45	27155	5650	64465882
PIK3CA-activated mutation	88.69	12.26	24	27176	501	64471031
Hepatic lesion	88.35	12.26	45	27155	5779	64465753
Metastases to the mediastinum	88.29	12.26	24	27176	510	64471022
Pseudocirrhosis	83.80	12.26	24	27176	621	64470911
Endometrial cancer	82.98	12.26	31	27169	1879	64469653
Endometrial hyperplasia	80.29	12.26	22	27178	482	64471050
Neuropathy peripheral	79.66	12.26	162	27038	117363	64354169
Uterine polyp	78.33	12.26	27	27173	1295	64470237
Carbohydrate antigen 15-3 increased	77.81	12.26	25	27175	962	64470570
Bone disorder	77.60	12.26	61	27139	16698	64454834
Breast mass	77.57	12.26	40	27160	5270	64466262
Tonsillar disorder	77.47	12.26	25	27175	976	64470556
Metastases to pleura	71.75	12.26	25	27175	1239	64470293
Endometrial atrophy	71.34	12.26	13	27187	34	64471498
Lymphadenopathy	66.56	12.26	90	27110	46596	64424936
Device related thrombosis	66.35	12.26	27	27173	2058	64469474
Nasal disorder	64.21	12.26	29	27171	2855	64468677
Osteolysis	61.81	12.26	28	27172	2775	64468757
Hormone receptor positive breast cancer	60.65	12.26	16	27184	302	64471230
Blood uric acid decreased	59.43	12.26	21	27179	1085	64470447
Acute promyelocytic leukaemia	58.38	12.26	22	27178	1366	64470166
Nail disorder	57.19	12.26	39	27161	8585	64462947
Bone pain	56.43	12.26	84	27116	47488	64424044
Eosinophil percentage increased	54.25	12.26	21	27179	1403	64470129
Completed suicide	54.00	12.26	14	27186	224400	64247132
Lymphoedema	52.32	12.26	39	27161	9866	64461666
Recurrent cancer	50.11	12.26	23	27177	2350	64469182
Metastases to chest wall	48.35	12.26	14	27186	377	64471155
Metastases to pelvis	48.10	12.26	15	27185	523	64471009
Disease recurrence	46.83	12.26	62	27138	31448	64440084
Pulmonary mass	46.54	12.26	54	27146	23962	64447570
Recall phenomenon	46.17	12.26	17	27183	989	64470543
Lymphangiosis carcinomatosa	45.97	12.26	20	27180	1801	64469731
Excessive eye blinking	45.95	12.26	18	27182	1242	64470290
Vitreous detachment	44.72	12.26	20	27180	1924	64469608
Endometrial hypertrophy	44.50	12.26	11	27189	158	64471374
Metastases to peritoneum	44.11	12.26	24	27176	3523	64468009
Breast cancer female	43.46	12.26	27	27173	5076	64466456
Cerebral venous thrombosis	43.36	12.26	21	27179	2420	64469112
Lymphadenopathy mediastinal	42.12	12.26	24	27176	3852	64467680
Bronchomalacia	41.53	12.26	11	27189	211	64471321
Peritoneal disorder	41.36	12.26	14	27186	635	64470897
Left ventricular dilatation	40.03	12.26	15	27185	917	64470615
Uterine cancer	39.95	12.26	21	27179	2877	64468655
Retinopathy	39.73	12.26	22	27178	3343	64468189
Metastases to ovary	39.72	12.26	11	27189	251	64471281
Invasive ductal breast carcinoma	38.75	12.26	25	27175	5017	64466515
Adnexa uteri mass	38.39	12.26	11	27189	285	64471247
Pulmonary embolism	38.16	12.26	142	27058	146214	64325318
Pneumonia	37.87	12.26	116	27084	559460	63912072
Endometrial thickening	37.84	12.26	10	27190	190	64471342
Endometriosis	37.83	12.26	20	27180	2772	64468760
Joint swelling	37.72	12.26	22	27178	215360	64256172
Ovarian cancer	37.28	12.26	21	27179	3298	64468234
Drug ineffective	35.93	12.26	208	26992	840039	63631493
Haematotoxicity	35.62	12.26	35	27165	12861	64458671
Vulvovaginal dryness	35.26	12.26	16	27184	1592	64469940
Maculopathy	34.16	12.26	18	27182	2478	64469054
Menopausal disorder	34.09	12.26	7	27193	40	64471492
Acute kidney injury	33.40	12.26	89	27111	449151	64022381
Palmar-plantar erythrodysaesthesia syndrome	32.90	12.26	50	27150	28769	64442763
Uterine leiomyoma	32.59	12.26	23	27177	5346	64466186
Pleural disorder	32.24	12.26	12	27188	720	64470812
Tooth extraction	32.16	12.26	29	27171	9572	64461960
Hypertriglyceridaemia	32.05	12.26	31	27169	11174	64460358
Metastases to eye	32.03	12.26	9	27191	217	64471315
Pathological fracture	31.75	12.26	28	27172	8977	64462555
Pleural effusion	31.50	12.26	121	27079	126438	64345094
Menopause	31.27	12.26	15	27185	1693	64469839
Blood creatinine decreased	31.21	12.26	25	27175	7025	64464507
Neutropenia	31.16	12.26	190	27010	239434	64232098
Ejection fraction decreased	30.25	12.26	48	27152	28659	64442873
Rheumatoid arthritis	29.89	12.26	16	27184	164278	64307254
Osteitis condensans	29.73	12.26	6	27194	31	64471501
Contraindicated product administered	29.47	12.26	5	27195	107824	64363708
Radiation pneumonitis	29.33	12.26	18	27182	3310	64468222
Metastases to thorax	29.30	12.26	8	27192	173	64471359
Tympanic membrane disorder	29.21	12.26	8	27192	175	64471357
Ascites	29.17	12.26	74	27126	61927	64409605
Radiation necrosis	28.61	12.26	9	27191	323	64471209
Therapeutic product effect decreased	28.11	12.26	7	27193	115344	64356188
Toxicity to various agents	27.77	12.26	71	27129	363442	64108090
Cardiac cirrhosis	27.75	12.26	8	27192	212	64471320
Tumour marker decreased	27.69	12.26	6	27194	46	64471486
Portal hypertension	27.42	12.26	22	27178	6197	64465335
Metastases to uterus	26.64	12.26	6	27194	56	64471476
Hypertransaminasaemia	26.64	12.26	23	27177	7168	64464364
Atrophic vulvovaginitis	26.49	12.26	12	27188	1189	64470343
Menopausal symptoms	26.21	12.26	13	27187	1577	64469955
Synovitis	26.20	12.26	5	27195	99085	64372447
Exposed bone in jaw	26.08	12.26	17	27183	3470	64468062
Malignant pleural effusion	26.03	12.26	16	27184	2951	64468581
Deprescribing error	25.25	12.26	5	27195	23	64471509
Mucosal toxicity	25.14	12.26	9	27191	483	64471049
Hepatic cirrhosis	25.04	12.26	42	27158	26256	64445276
Hepatic steatosis	24.96	12.26	46	27154	30961	64440571
Left ventricular dysfunction	24.63	12.26	33	27167	16921	64454611
Metastatic neoplasm	24.61	12.26	18	27182	4424	64467108
Sepsis	24.49	12.26	37	27163	230304	64241228
Fibrous histiocytoma	24.34	12.26	9	27191	530	64471002
Vaginal haemorrhage	24.15	12.26	35	27165	19309	64452223
Gastrointestinal haemorrhage	23.89	12.26	13	27187	132299	64339233
Lower limb fracture	23.84	12.26	29	27171	13516	64458016
Gastrointestinal toxicity	23.83	12.26	19	27181	5303	64466229
Sequestrectomy	23.66	12.26	10	27190	839	64470693
Disturbance in attention	23.62	12.26	53	27147	41021	64430511
Breast cancer in situ	23.40	12.26	10	27190	862	64470670
Paraesthesia	23.06	12.26	115	27085	134407	64337125
Septic shock	22.77	12.26	8	27192	105429	64366103
RET gene mutation	22.70	12.26	4	27196	8	64471524
Systemic lupus erythematosus	22.58	12.26	3	27197	77609	64393923
Myocardial infarction	22.53	12.26	22	27178	165799	64305733
Injection site extravasation	22.43	12.26	22	27178	8064	64463468
Radiation skin injury	22.30	12.26	11	27189	1319	64470213
Hypotension	22.30	12.26	84	27116	380890	64090642
Cervical polyp	22.14	12.26	6	27194	126	64471406
Adenomyosis	21.92	12.26	7	27193	264	64471268
Porphyria non-acute	21.80	12.26	9	27191	712	64470820
Invasive breast carcinoma	21.72	12.26	8	27192	466	64471066
Gingival bleeding	21.72	12.26	29	27171	14825	64456707
Therapy partial responder	21.47	12.26	24	27176	10224	64461308
Cardiotoxicity	21.43	12.26	24	27176	10250	64461282
Lymphangioleiomyomatosis	21.42	12.26	6	27194	143	64471389
Osteosclerosis	21.31	12.26	15	27185	3471	64468061
Abdominal lymphadenopathy	20.95	12.26	10	27190	1116	64470416
Toothache	20.94	12.26	31	27169	17428	64454104
Invasive lobular breast carcinoma	20.63	12.26	8	27192	537	64470995
Leiomyoma	20.57	12.26	7	27193	323	64471209
Arteriovenous malformation	20.54	12.26	11	27189	1565	64469967
Amenorrhoea	20.43	12.26	19	27181	6520	64465012
Hepatic enzyme increased	20.39	12.26	15	27185	129928	64341604
Onycholysis	20.22	12.26	11	27189	1615	64469917
Oestradiol abnormal	20.10	12.26	4	27196	19	64471513
Tumour invasion	20.07	12.26	7	27193	348	64471184
Sensory loss	19.93	12.26	23	27177	10146	64461386
Breast disorder	19.85	12.26	11	27189	1673	64469859
Atypical femur fracture	19.41	12.26	16	27184	4682	64466850
Metastases to meninges	19.30	12.26	13	27187	2802	64468730
Ovarian hyperstimulation syndrome	19.18	12.26	13	27187	2832	64468700
Superior sagittal sinus thrombosis	19.18	12.26	9	27191	967	64470565
Meningeal disorder	19.03	12.26	7	27193	406	64471126
Madarosis	19.01	12.26	12	27188	2318	64469214
Postmenopausal haemorrhage	18.66	12.26	10	27190	1425	64470107
Drug abuse	18.64	12.26	17	27183	132357	64339175
Cortisol increased	18.58	12.26	7	27193	434	64471098
Vertebral lesion	18.54	12.26	7	27193	437	64471095
Ovarian cyst	18.44	12.26	23	27177	10995	64460537
Deafness	18.39	12.26	30	27170	18329	64453203
Multiple organ dysfunction syndrome	18.26	12.26	10	27190	101403	64370129
Metastases to stomach	18.17	12.26	6	27194	252	64471280
Polyneuropathy	17.92	12.26	31	27169	19863	64451669
Respiratory tract inflammation	17.76	12.26	8	27192	782	64470750
Glossodynia	17.67	12.26	3	27197	64693	64406839
Corneal degeneration	17.66	12.26	5	27195	124	64471408
Bone sequestrum	17.61	12.26	9	27191	1163	64470369
Pain in jaw	17.49	12.26	47	27153	40708	64430824
Oxygen saturation decreased	17.30	12.26	12	27188	107164	64364368
Acarodermatitis	17.19	12.26	9	27191	1223	64470309
Breast neoplasm	17.15	12.26	8	27192	848	64470684
Central nervous system lesion	17.12	12.26	23	27177	11826	64459706
Eastern Cooperative Oncology Group performance status worsened	17.08	12.26	9	27191	1239	64470293
Hydrothorax	17.02	12.26	9	27191	1248	64470284
Liver scan abnormal	16.77	12.26	4	27196	49	64471483
Nasal dryness	16.68	12.26	13	27187	3513	64468019
Paraneoplastic syndrome	16.66	12.26	8	27192	905	64470627
Trigger finger	16.61	12.26	13	27187	3532	64468000
Reversible cerebral vasoconstriction syndrome	16.50	12.26	11	27189	2331	64469201
Corneal graft rejection	16.48	12.26	4	27196	53	64471479
Treatment failure	16.45	12.26	15	27185	116801	64354731
Actinomycosis	16.42	12.26	8	27192	934	64470598
Neutrophilia	16.35	12.26	17	27183	6677	64464855
Hair texture abnormal	16.25	12.26	12	27188	2992	64468540
Intermenstrual bleeding	16.23	12.26	15	27185	5110	64466422
Wound	16.17	12.26	6	27194	76471	64395061
Metabolic acidosis	15.99	12.26	5	27195	70953	64400579
Cardio-respiratory arrest	15.91	12.26	11	27189	98382	64373150
Non-alcoholic steatohepatitis	15.80	12.26	10	27190	1942	64469590
Rapidly progressive osteoarthritis	15.70	12.26	3	27197	11	64471521
Haemangioma of liver	15.53	12.26	8	27192	1052	64470480
Corneal disorder	15.45	12.26	10	27190	2017	64469515
Breath odour	15.40	12.26	9	27191	1515	64470017
Alopecia areata	15.38	12.26	9	27191	1519	64470013
Diabetic hyperosmolar coma	15.31	12.26	7	27193	709	64470823
BRCA2 gene mutation	15.29	12.26	4	27196	73	64471459
Hypersensitivity	15.27	12.26	38	27162	196414	64275118
Respiratory tract oedema	15.18	12.26	7	27193	723	64470809
Adenocarcinoma	15.08	12.26	12	27188	3339	64468193
Jaw operation	14.92	12.26	7	27193	752	64470780
Spinal cord compression	14.87	12.26	15	27185	5688	64465844
Debridement	14.86	12.26	9	27191	1617	64469915
Hysteroscopy	14.78	12.26	3	27197	16	64471516
Oral mucosal hypertrophy	14.78	12.26	3	27197	16	64471516
Breast reconstruction	14.67	12.26	4	27196	86	64471446
Portal vein thrombosis	14.64	12.26	14	27186	4977	64466555
Adenoid cystic carcinoma	14.63	12.26	3	27197	17	64471515
Central nervous system infection	14.63	12.26	8	27192	1186	64470346
Metastases to breast	14.50	12.26	5	27195	240	64471292
Retinal artery occlusion	14.38	12.26	11	27189	2892	64468640
Encapsulating peritoneal sclerosis	14.36	12.26	7	27193	818	64470714
Oestradiol increased	14.33	12.26	4	27196	94	64471438
Respiratory failure	14.30	12.26	29	27171	161154	64310378
Cystoid macular oedema	14.14	12.26	9	27191	1765	64469767
Dyspareunia	14.12	12.26	9	27191	1768	64469764
Chronic hepatic failure	14.09	12.26	7	27193	852	64470680
Sinusitis	14.04	12.26	25	27175	145903	64325629
Hair colour changes	13.97	12.26	12	27188	3715	64467817
Neoplasm recurrence	13.93	12.26	12	27188	3727	64467805
Atrial thrombosis	13.92	12.26	11	27189	3031	64468501
Back pain	13.91	12.26	164	27036	250007	64221525
Coma	13.89	12.26	10	27190	87605	64383927
Breast pain	13.88	12.26	16	27184	7045	64464487
Performance status decreased	13.78	12.26	14	27186	5350	64466182
Carcinoembryonic antigen increased	13.69	12.26	9	27191	1864	64469668
Pneumonia aspiration	13.67	12.26	4	27196	59267	64412265
Endometrial adenocarcinoma	13.55	12.26	7	27193	925	64470607
Encephalopathy	13.51	12.26	4	27196	58815	64412717
Dental operation	13.41	12.26	7	27193	945	64470587
Intentional overdose	13.33	12.26	11	27189	89933	64381599
Ovarian granulosa-theca cell tumour	13.32	12.26	3	27197	28	64471504
Mucosal inflammation	13.30	12.26	57	27143	62527	64409005
Femur fracture	13.29	12.26	38	27162	34097	64437435
Coagulation factor V level decreased	13.26	12.26	6	27194	593	64470939
Metastases to muscle	13.11	12.26	5	27195	321	64471211
Skin exfoliation	12.91	12.26	45	27155	44840	64426692
Aeromonas infection	12.89	12.26	5	27195	336	64471196
Product use issue	12.87	12.26	28	27172	151687	64319845
Abdominal discomfort	12.85	12.26	37	27163	182285	64289247
Gingivitis	12.84	12.26	16	27184	7643	64463889
Ocular toxicity	12.83	12.26	6	27194	640	64470892
Atypical fracture	12.74	12.26	6	27194	650	64470882
Cardiomyopathy	12.70	12.26	31	27169	25325	64446207
Ventricular hypokinesia	12.65	12.26	16	27184	7753	64463779
Rhabdomyolysis	12.65	12.26	12	27188	91714	64379818
Rhabdomyosarcoma	12.63	12.26	4	27196	147	64471385
Unresponsive to stimuli	12.38	12.26	3	27197	50390	64421142
Neoplasm	12.29	12.26	15	27185	7016	64464516

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L02BA01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONE ANTAGONISTS AND RELATED AGENTS Anti-estrogens
FDA MoA	N0000000168	Selective Estrogen Receptor Modulators
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D018931	Antineoplastic Agents, Hormonal
MeSH PA	D050071	Bone Density Conservation Agents
MeSH PA	D004965	Estrogen Antagonists
MeSH PA	D020847	Estrogen Receptor Modulators
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D020845	Selective Estrogen Receptor Modulators
FDA EPC	N0000175826	Estrogen Agonist/Antagonist
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:37700	protein kinase C inhibitors
CHEBI has role	CHEBI:48422	angiogenesis antagonist
CHEBI has role	CHEBI:50646	antiosteoporotic
CHEBI has role	CHEBI:50792	estrogen receptor antagonists
CHEBI has role	CHEBI:50837	oestrogen antagonist
CHEBI has role	CHEBI:62872	quinoline oxidase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Infiltrating duct carcinoma of breast	indication	408643008	DOID:3008
Carcinoma of female breast	indication	447782002
Prevention of Breast Carcinoma	indication
Pain of breast	off-label use	53430007
Endometrial carcinoma	off-label use	254878006	DOID:2871
Malignant tumor of ovary	off-label use	363443007	DOID:2394
Hypercalcemia	contraindication	66931009	DOID:12678
Leukopenia	contraindication	84828003	DOID:615
Bilateral cataracts	contraindication	95722004
Deep venous thrombosis	contraindication	128053003
Cerebrovascular accident	contraindication	230690007
Pulmonary thromboembolism	contraindication	233935004
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Thromboembolic disorder	contraindication	371039008
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.61	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN	MODULATOR	Ki	7.51	CHEMBL	CHEMBL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	5.00	DRUG MATRIX
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN		IC50	4.46	WOMBAT-PK
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN		IC50	5.36	DRUG MATRIX
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	5.15	DRUG MATRIX
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.37	DRUG MATRIX
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	5.34	DRUG MATRIX
Estrogen-related receptor gamma	Nuclear hormone receptor	P62508	ERR3_HUMAN		Ki	7.10	WOMBAT-PK
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN		Ki	5.40	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.14	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.50	WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.80	CHEMBL
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Enzyme	Q15125	EBP_HUMAN		Ki	8.30	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		Ki	7	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.91	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.84	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.16	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.86	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.88	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.62	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.98	CHEMBL
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.79	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.44	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.03	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.17	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.56	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.20	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.17	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	5.73	DRUG MATRIX
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	5.66	WOMBAT-PK
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	5.24	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.84	DRUG MATRIX
Adenosine receptor A1	GPCR	P30542	AA1R_HUMAN		Ki	4.86	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.68	DRUG MATRIX
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN		Ki	7.46	WOMBAT-PK
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	5.41	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	5.61	DRUG MATRIX
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	5.20	DRUG MATRIX
Progesterone receptor	Nuclear hormone receptor	P06401	PRGR_HUMAN		IC50	6.89	CHEMBL
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	5.33	DRUG MATRIX
Estrogen receptor beta	Nuclear hormone receptor	Q92731	ESR2_HUMAN		IC50	5.91	WOMBAT-PK
G-protein coupled estrogen receptor 1	GPCR	Q99527	GPER1_HUMAN		IC50	7.50	WOMBAT-PK
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	5.45	DRUG MATRIX
Substance-P receptor	GPCR	P25103	NK1R_HUMAN		Ki	5.07	DRUG MATRIX
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		IC50	5.10	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.92	DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		IC50	5.53	DRUG MATRIX
Glucosylceramidase	Enzyme	P04062	GLCM_HUMAN		EC50	5.60	CHEMBL
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN		IC50	6.04	DRUG MATRIX
Steroid hormone receptor ERR1	Nuclear hormone receptor	P11474	ERR1_HUMAN		IC50	6.70	CHEMBL
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.91	DRUG MATRIX
B2 bradykinin receptor	GPCR	P30411	BKRB2_HUMAN		Ki	4.92	DRUG MATRIX
Melanocortin receptor 4	GPCR	P32245	MC4R_HUMAN		Ki	4.53	DRUG MATRIX
Melanocortin receptor 5	GPCR	P33032	MC5R_HUMAN		Ki	4.60	DRUG MATRIX
Melanocortin receptor 3	GPCR	P41968	MC3R_HUMAN		Ki	4.76	DRUG MATRIX
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Enzyme	Q08209	PP2BA_HUMAN		IC50	4.52	DRUG MATRIX
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	4.06	WOMBAT-PK
Emopamil-binding protein-like	Enzyme	Q9BY08	EBPL_HUMAN		Ki	8.55	CHEMBL
Anti-estrogen binding site (AEBS)	Enzyme	Q15125 Q9UBM7	EBP_HUMAN DHCR7_HUMAN		Kd	9	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	4.82	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.42	DRUG MATRIX
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	5.59	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	4.66	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	4.92	CHEMBL
C-8 sterol isomerase	Enzyme		ERG2_YEAST		Ki	5.82	CHEMBL
Sodium/potassium-transporting ATPase subunit alpha-2	Ion channel		AT1A2_PIG		IC50	4.81	DRUG MATRIX
Transcriptional activator protein luxR	Unclassified		LUXR_ALIFS		IC50	4.40	CHEMBL

External reference:

ID	Source
4019939	VUID
N0000148024	NUI
D00966	KEGG_DRUG
54965-24-1	SECONDARY_CAS_RN
4018462	VANDF
4019939	VANDF
C0039286	UMLSCUI
CHEBI:41774	CHEBI
CTX	PDB_CHEM_ID
CHEMBL83	ChEMBL_ID
DB00675	DRUGBANK_ID
CHEMBL786	ChEMBL_ID
D013629	MESH_DESCRIPTOR_UI
2733526	PUBCHEM_CID
1016	IUPHAR_LIGAND_ID
3299	INN_ID
094ZI81Y45	UNII
10324	RXNORM
2281	MMSL
4270	MMSL
5540	MMSL
d00381	MMSL
002670	NDDF
004826	NDDF
373345002	SNOMEDCT_US
41395001	SNOMEDCT_US
75959001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0144	TABLET	10 mg	ORAL	ANDA	26 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0274	TABLET	20 mg	ORAL	ANDA	26 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2472	TABLET	10 mg	ORAL	ANDA	25 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2472	TABLET	10 mg	ORAL	ANDA	25 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2473	TABLET	20 mg	ORAL	ANDA	25 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2473	TABLET	20 mg	ORAL	ANDA	25 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0485	TABLET	10 mg	ORAL	ANDA	25 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0942	TABLET	20 mg	ORAL	ANDA	25 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	51407-439	TABLET, FILM COATED	10 mg	ORAL	ANDA	28 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	51407-439	TABLET, FILM COATED	10 mg	ORAL	ANDA	28 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	51407-440	TABLET, FILM COATED	20 mg	ORAL	ANDA	28 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	51407-440	TABLET, FILM COATED	20 mg	ORAL	ANDA	28 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	51862-446	TABLET, FILM COATED	20 mg	ORAL	ANDA	26 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	51862-447	TABLET, FILM COATED	10 mg	ORAL	ANDA	26 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	51862-642	TABLET, FILM COATED	10 mg	ORAL	ANDA	28 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	51862-642	TABLET, FILM COATED	10 mg	ORAL	ANDA	28 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	51862-643	TABLET, FILM COATED	20 mg	ORAL	ANDA	28 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	51862-643	TABLET, FILM COATED	20 mg	ORAL	ANDA	28 sections
SOLTAMOX	HUMAN PRESCRIPTION DRUG LABEL	1	51862-682	LIQUID	20 mg	ORAL	NDA	33 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3004	TABLET, FILM COATED	10 mg	ORAL	ANDA	26 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4287	TABLET, FILM COATED	20 mg	ORAL	ANDA	26 sections
Tamoxifen Citrate	Human Prescription Drug Label	1	59651-299	TABLET, FILM COATED	10 mg	ORAL	ANDA	24 sections
Tamoxifen Citrate	Human Prescription Drug Label	1	59651-300	TABLET, FILM COATED	20 mg	ORAL	ANDA	24 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	60429-909	TABLET, FILM COATED	10 mg	ORAL	ANDA	26 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	60429-909	TABLET, FILM COATED	10 mg	ORAL	ANDA	26 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	60429-910	TABLET, FILM COATED	20 mg	ORAL	ANDA	26 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	60429-910	TABLET, FILM COATED	20 mg	ORAL	ANDA	26 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	63187-976	TABLET	20 mg	ORAL	ANDA	25 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	63739-143	TABLET, FILM COATED	10 mg	ORAL	ANDA	28 sections
Tamoxifen Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	63739-269	TABLET, FILM COATED	10 mg	ORAL	ANDA	26 sections